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Abstract 
Background: Vascular shear stress promotes endothelial cell sprouting in vitro. The impact of hemodynamic forces 
on microRNA (miRNA) and gene expression within growing vascular networks in vivo, however, remain poorly investi‑
gated. Arteriovenous (AV) shunts are an established model for induction of neoangiogenesis in vivo and can serve as 
a tool for analysis of hemodynamic effects on miRNA and gene expression profiles over time.
Methods: AV shunts were microsurgically created in rats and explanted on postoperative days 5, 10 and 15. Neoan‑
giogenesis was confirmed by histologic analysis and micro‑computed tomography. MiRNA and gene expression pro‑
files were determined in tissue specimens from AV shunts by microarray analysis and quantitative real‑time polymer‑
ase chain reaction and compared with sham‑operated veins by bioinformatics analysis. Changes in protein expression 
within AV shunt endothelial cells were determined by immunohistochemistry.
Results: Samples from AV shunts exhibited a strong overexpression of proangiogenic cytokines, oxygenation‑
associated genes (HIF1A, HMOX1), and angiopoetic growth factors. Significant inverse correlations of the expressions 
of miR‑223‑3p, miR‑130b‑3p, miR‑19b‑3p, miR‑449a‑5p, and miR‑511‑3p which were up‑regulated in AV shunts, and 
miR‑27b‑3p, miR‑10b‑5p, let‑7b‑5p, and let‑7c‑5p, which were down‑regulated in AV shunts, with their predicted 
interacting targets C–X–C chemokine receptor 2 (CXCR2), interleukin‑1 alpha (IL1A), ephrin receptor kinase 2 (EPHA2), 
synaptojanin‑2 binding protein (SYNJ2BP), forkhead box C1 (FOXC1) were present. CXCL2 and IL1A overexpression in 
AV shunt endothelium was confirmed at the protein level by immunohistochemistry.
Conclusions: Our data indicate that flow‑stimulated angiogenesis is determined by an upregulation of cytokines, 
oxygenation associated genes and miRNA‑dependent regulation of FOXC1, EPHA2 and SYNJ2BP.
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Background
Vascular remodeling and angiogenesis play important 
roles in the pathophysiology of cardiovascular diseases. 
The development of new blood vessels is governed 
by an interplay of biochemical and mechanical stim-
uli. The pulsatile blood flow generated by the cardiac 
cycle exposes endothelial cells (ECs) to two mechani-
cal forces, namely circumferential stretch acting per-
pendicularly, and shear stress acting tangentially to the 
vascular wall [1]. Elevated shear stress has been shown 
to promote EC migration and regeneration, as well as 
differentiation of embryonic stem cells into ECs [2, 3]. 
In vitro studies have shown that mechanical forces act-
ing on ECs and vascular smooth muscle cells (VSMCs) 
are translated into biochemical signals by mechanosen-
sory proteins [4, 5]. These promote intracellular path-
ways, which lead to altered gene expression profiles [6, 
7] with up-regulated proangiogenic factors like vascu-
lar endothelial growth factor (VEGF) [3].
Angiogenesis, however, is a delicately regulated pro-
cess, which goes far beyond EC sprouting, and requires 
a concerted action of ECs, VSMCs, as well as signals 
from the extracellular matrix (ECM) and cells like mac-
rophages and fibroblasts chemotactically attracted 
to areas of neoangiogenesis [8, 9]. In  vitro studies on 
ECs have shown that elevated shear stress induces the 
expression of microRNAs (miRNAs) that affect vascular 
remodeling and angiogenesis [10, 11]. Current knowl-
edge of differential signaling in angiogenesis largely 
stems from in  vitro studies by means of EC sprouting 
assays or co-culture systems [12]. Still, these models are 
limited in representing in  vivo physiologic conditions. 
The development of new therapeutic strategies targeting 
angiogenesis requires more realistic model systems and a 
more detailed understanding of the complex in vivo envi-
ronment determining angiogenic processes. Therefore, 
studies integrating the molecular signals from different 
cellular players and miRNAs which govern angiogenesis 
are needed.
So far, evidence is lacking on how elevated shear stress 
in vivo influences miRNA expression profiles within the 
vascular wall, and to what extent altered miRNA signa-
tures influence the expression levels of pro- and anti-
angiogenic genes. This knowledge may soon gain clinical 
value as RNA-based therapeutics are an emerging field 
in cardiovascular pharmacology, and studies in small 
and large animal models of cardiovascular diseases have 
yielded promising results [13–15]. MiRNA-mediated 
silencing of anti-angiogenic genes by means of synthetic 
RNA mimics appears to be a promising approach for the 
promotion of local neoangiogenesis in ischemic myo-
cardium [16]. Conversely, miRNA-mediated down-reg-
ulation of proangiogenic genes constitutes a treatment 
strategy for the suppression of neoangiogenesis in oncol-
ogy patients [17].
Arteriovenous (AV) shunts are an established model 
for in vivo induction of neoangiogenesis through elevated 
blood flow [18, 19]. Here, an AV shunt is microsurgically 
created by interposing a vein graft between the saphen-
ous artery and vein on the hind limbs of a rat [20], leading 
to an increase in blood flow by 4.5-fold within the vascu-
lar construct [21]. Elevated shear stress on the vascular 
wall due to increased blood flow triggers rapid sprouting 
of new blood vessels from the AV shunt leading to the 
development of a microvascular network within 15 days 
[21]. Therefore, AV shunts are an ideal tool for in  vivo 
analyses of the effects of elevated vascular shear stress 
on miRNA and gene expression profiles over time, which 
regulate flow-stimulated angiogenesis and remodeling.
We determined the expression profiles of 758 miRNAs 
and 30,584 messenger RNAs (mRNAs) by microarray 
analysis in venous tissue samples from rat AV shunts after 
exposure to elevated blood flow for 5, 10 and 15  days 
(n = 7 per group) (Fig. 1). Expression profiles were com-
pared to sham-operated veins (end-to-end anastomosis, 
n = 8) in order to eliminate effects of the surgical pro-
cedure and mechanical influence caused by the opera-
tion itself on miRNA and gene expression. To identify 
miRNA–mRNA interactions that are relevant for the 
regulation of angiogenic processes, a gene ontology (GO) 
enrichment analysis was performed with GeneTrail2 [22, 
23]. We determined miRNA/mRNA pairs with inverse 
correlations (r < 0.5) and a P-value < 5 × 10−5, which 
were associated with GO terms for positive, respec-
tively negative regulation of angiogenic processes (A 
list of employed GO terms is shown in Additional file 1: 
Table  S1). We used TargetScan release 7.1 for miRNA/
mRNA target prediction analysis since it has proven to 
be the most robust prediction tool for identification of 
miRNA/mRNA target interactions [24, 25]. In mammals, 
cumulative weighted context++ scores of the binding 
sites are calculated and used for prediction of efficacy 
of targeting according to Agarwal et  al. [24]. The con-
text++ model has shown to be more predictive than any 
previously published model, being as predictive as most 
in  vivo crosslinking approaches [24]. Neoangiogenesis 
originating from AV shunts was assessed by morphologi-
cal analysis of histologic cross-sections and micro-com-
puted tomography (micro-CT). The expression changes 
of strongly deregulated mRNAs were confirmed at the 
protein level by immunohistochemical analysis.
Methods
Microsurgical AV shunt creation
The experiments were performed in accordance with the 
German Animal Welfare Act and approved by the local 
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governmental authorities [Landesuntersuchungsamt 
Rheinland-Pfalz (G15-7-047)] on 47 female Sprague–
Dawley rats (Charles River Laboratories, Sulzfeld, Ger-
many) weighing 280–320  g at ages 11–15  months. The 
animals had access to food and water and were kept at a 
12 h dark/light cycle throughout. All surgical procedures 
were carried out under inhalation anesthesia with isoflu-
rane (5% for induction and 2.5% for maintenance) in pure 
oxygen with a flow of 0.3 l/min. At the end of the experi-
ments, the animals were euthanized by intracardial injec-
tion of pentobarbital under deep anesthesia. All surgical 
procedures were performed using a surgical microscope 
(magnification 16×, OPMI pico, Carl Zeiss, Germany). 
All rats received heparin (80 IU/kg i.v.) after completion 
of the anastomoses. Buprenorphin (0.05 mg/kg s.c.) was 
administered for analgesia preoperatively and twice daily 
for 2 days postoperatively. For AV shunt creation in the 
rats, the saphenous veins and arteries were exposed and 
dissected after midventral cutaneous incision on both 
hind limbs. A 20 mm long saphenous vein graft was har-
vested from the left leg and anastomosed between the 
right saphenous artery and vein in an end-to-end fash-
ion, thereby creating an AV shunt (Fig.  1). The patency 
of both microanastomoses was assessed by observation 
of pulsatility and double occlusion test. Subsequently, 
the construct was placed into a Teflon isolation cham-
ber (height 6  mm × diameter 12  mm, Harhaus Devices, 
Remscheid, Germany) between two layers of acellular 
dermal substitute (ADS) (MatriDerm, MedSkin Solu-
tions Dr. Suwelack, Billerbeck, Germany) with a thick-
ness of 2 mm. The chamber was closed with a lid (height 
2  mm × diameter 14  mm) and sutured onto the under-
lying adductor fascia. The wounds on both thighs were 
subsequently closed with running subcutaneous and 
cutaneous sutures. The surgical technique is described 
elsewhere in detail [20]. For the sham operation the 
Fig. 1 a Experimental setup and micro CT analysis. An arteriovenous shunt is microsurgically created on a rat’s hind limb by anastomosing a 
saphenous vein graft (green) from the contralateral leg between saphenous artery (red) and vein (blue). b The AV shunt is placed around four pins 
(P) for stabilization within a Teflon chamber (C). Two layers of acellular dermal substitute (ADS) are placed below and above the vascular construct 
(upper layer not shown). A saphenous artery, V saphenous vein, VG vein graft. c Analysis of an explanted AV shunt on postoperative day 15 by 
micro‑computed tomography revealed a dense microvascular sprouting from the shunt vessels
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saphenous vein was severed and subsequently sutured 
by end-to-end anastomosis. Sham-operated veins were 
explanted on postoperative day (POD) 5 (n = 10).
Sample collection and RNA isolation
For explantation, the Teflon chambers containing the 
vascular constructs were exposed by midventral incision 
on the rats’ hind limbs. After removal of the lid, the ves-
sels were dissected from the surrounding ADS under the 
microscope, and the AV shunt was divided at the level 
of the two anastomoses separating the vein interposi-
tion graft from the saphenous artery and vein. The vein 
grafts were harvested, and care was taken to free the ves-
sels from all attached ADS contents and suture material 
under the microscope. Tissue specimens were immedi-
ately placed into RNAlater solution (Applied Biosystems, 
Foster City, CA, USA) and stored at − 80 °C according to 
the manufacturer’s recommendations until further analy-
sis. RNA isolation was performed with the Qiagen RNe-
asy mini Kit using the manufacturer’s protocol. Tissue 
samples were homogenized in 700 µl QIAzol Lysis Rea-
gent (Qiagen, Hilden, Germany) using a TissueLyser II 
(Qiagen). RNA quality and quantity were assessed with a 
NanoDrop 2000 Spectrophotometer (Thermo Scientific, 
Waltham, MA, USA). All samples had a 260/280 ratio of 
1.8–2.1 and were used for further analysis. RNA integrity 
was determined using the Agilent 6000 Nano Kit on an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA).
MicroRNA microarray analysis
MiRNA expression profiling was performed using Sure-
Print™ 8 × 15  K Rat v21 miRNA microarrays (Agilent 
Technologies, Santa Clara, CA, USA). These microar-
rays contain 719 mature miRNAs of miRBase v21. All 
procedures were carried out according to the manufac-
turer’s recommendations. In brief, a total of 100 ng total 
RNA from each sample was dephosphorylated by incu-
bation with calf intestinal phosphatase (CIP) at 37  °C 
for 30 min and denatured with 100% dimethyl sulfoxide 
(DMSO) at 100 °C for 7 min. Samples were labeled with 
pCp-Cy3 with the use of T4 ligase at 16  °C incubation 
for 2  h. Each labeled RNA sample was then hybridized 
onto an individual subarray, with each array containing 
probes for 306 miRNAs. Hybridizations were performed 
in SureHyb chambers (Agilent Technologies) at 55 °C for 
20 h with rotation. Arrays were then washed, dried and 
scanned at a resolution of 3  μm double-pass using an 
Agilent G2565C Microarray Scanner. Data were acquired 
using Agilent AGW Feature Extraction software version 
10.10.11.
mRNA microarray analysis
MRNA expression profiling was performed using Sure-
Print™ 8 × 60 K G3 Rat Gene Expression v2 microarrays 
and one-color labeling kit (Agilent Technologies). These 
microarrays contained 30,584 biological features. All pro-
cedures were carried out according to the manufacturer’s 
protocol. In brief, 100  ng total RNA from each sample 
were reversely transcribed using Oligo-dT-T7 promotor 
primers 40  °C for 2  h to obtain cDNA. Labeled cDNA 
was generated using Cy3-pCp and T7 RNA polymerase 
at 40 °C for 2 h and subsequently purified using the RNe-
asy Mini kit (Qiagen, Hilden, Germany). Purified cDNA 
was measured with the NanoDrop 2000 Spectrophotom-
eter (Thermo Scientific, Waltham, MA, USA) to ensure 
that labeled cDNA was of sufficient quality for hybridi-
zation. 600 nanograms (ng) of labeled cDNA were then 
hybridized onto the microarray slide at 65  °C for 17  h 
with 10 rpm rotation in the SureHyb chambers (Agilent 
Technologies). After washing and drying, the array was 
scanned in the Agilent G2565BA Microarray Scanner 
with 5 µm resolution. Data were acquired using the Agi-
lent AGW Feature Extraction software version 10.10.11.
Reverse transcription and quantitative real‑time PCR
Quantitative real-time polymerase chain reaction (RT-
qPCR) was performed to validate the microarray results 
on a StepOnePlus™ real-time PCR system (Applied Bio-
systems, Foster City, CA, USA) with the miScript PCR 
System along with miScript and QuantiTect Primer 
Assays (Qiagen, Hilden, Germany). From 29 samples 
used for microarray analysis, 28 samples yielded a suffi-
cient RNA quantity allowing for RT-qPCR validation of 
both miRNA and mRNA expression. All steps were car-
ried out according to the manufacturer’s recommenda-
tions. In brief, 400 ng of RNA were converted into cDNA 
using the miScript II RT Kit (Qiagen). During the reverse 
transcription step, 5× miScript HiFlex Buffer was used to 
promote conversion of all RNA into cDNA. The result-
ing cDNA was then diluted to have 0.5 ng/µl for miRNA 
and 2.5  ng/µl for mRNA. All reverse transcription PCR 
(RT-PCR) experiments were performed using the QIA-
gility™ automated PCR setup (Qiagen) before performing 
RT-qPCR analysis on a StepOnePlus™ Real-Time PCR 
system (Applied Biosystems). Briefly, each miRNA PCR 
reaction contained 2 µl cDNA, 10 µl QuantiTect SYBR 
Green PCR Mix, 2 µl miScript Universal Primer and 2 µl 
miScript Primer Assays for rno-miR-340-5p, rno-miR-
19b-3p, rno-miR-223-3p, rno-miR-31a-5p, rno-miR-
210-3p, rno-let-7b-5p, and rno-let-7c-5p plus RNase-free 
water to a total volume of 20 µl, and was placed into 
an individual well of a 96-well plate. Each mRNA PCR 
reaction contained, 2 µl cDNA, 10 µl QuantiTect SYBR 
Green PCR Mix and 2 µl QuantiTect Primer Assay 
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for hypoxia-inducible factor 1-alpha (HIF1A), toll like 
receptor 6 (TLR6), vascular endothelial growth factor 
A (VEGFA), thrombospondin 3 (THBS3), and N-myc 
downstream regulated gene 2 (NDRG2) plus RNase-
free water amounting to a total volume of 20 µl, and was 
placed into an individual well of a 96-well plate. Reac-
tions were run with the following thermal cycling param-
eters: initial activation step 95 °C for 15 min followed by 
40 cycles at 94 °C for 15 s (denaturation), 55 °C for 30 s 
(annealing), and 70 °C for 30 s (extension). Then final dis-
sociation curves (melting curves) were made and PCR 
plates were kept at 4 °C until they were taken out of the 
PCR machine. QuantiTect Primer Assays for hypoxan-
thine-guanine phosphoribosyltransferase (HPRT) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were chosen as reference genes for mRNA normaliza-
tion, and rno-miR-93-5p and rno-RNU6B were chosen as 
endogenous controls for miRNA normalization. In addi-
tion, a no template control (NTC) and no reverse tran-
scriptase control (NRT) were included in each run. All 
RT-qPCR experiments were performed in triplicate.
Histological analysis
In order to visualize the expanding functional vasculature 
around the AV shunts over time and analyze endothelial 
protein expression, a histological analysis of AV shunts 
and control veins was performed in 17 animals (POD 5: 
n = 3, POD 10: n = 6, POD 15: n = 6, control veins: n = 2). 
Functional vessels on histologic cross-sections were 
highlighted by perfusion with black India ink (Windsor 
& Newton, London, England). After abdominal incision 
the distal descending aortas of the rats were cannulated 
with a 24-gauge catheter and flushed with heparin solu-
tion (100  IU/ml) followed by 30  ml of warm Indian ink 
solution. Subsequently the constructs were explanted 
and fixed in 4% paraformaldehyde (PFA) in phosphate-
buffered saline (PBS), followed by dehydration and 
embedding into paraffin. Histological cross sections were 
obtained perpendicularly to the longitudinal main ves-
sel axis. Hematoxylin and eosin staining was performed 
according to standard protocols. Stained slides were visu-
alized by bright field microscopy and recorded using with 
the Axio Vision 4 software (Carl Zeiss Microscopy, Jena, 
Germany).
Immunohistochemistry
Serial sections of 4  µm thickness were generated and 
immunostained for C–X–C motif chemokine ligand 2 
(CXCL2) (unconjugated rabbit polyclonal anti-CXCL2 
antibody, LS-C-415005-100, LifeSpan BioSciences, 
Seattle, WA, USA) and IL1A (anti-IL1A primary anti-
body, OAAN00770, Aviva Systems Biology, San Diego, 
CA, USA). Staining was performed using a BenchMark 
XT immunostainer (Roche Diagnostics, Germany). An 
UltraView DAB detection and amplification kit (Roche 
Diagnostics, Germany) was used and the slides were 
counterstained with hematoxylin for 4  min and post-
counterstained with bluing agent for 4  min. Then, the 
slides were washed and dehydrated in 70% to 100% rea-
gent alcohol baths and xylenes baths before applying cov-
erslips. Standardized images of one complete vessel cross 
section were obtained at 63× magnification (Axio Vision 
4, Carl Zeiss Microscopy) under standardized condi-
tions for white balance and exposure time (161.2  ms). 
The images were cropped to non-overlapping areas of 
165 × 220 µm covering the complete endothelium. Quan-
titative assessment of endothelial protein expression was 
performed with the freeware ImageJ (NIH, Bethesda, 
MD, USA, https ://image j.nih.gov). Images were con-
verted into grayscale and per cross section 24 ECs were 
manually selected as regions of interest (ROI). Integrated 
Density (defined as the product of area (µm2) and mean 
gray value) was assessed in each of the 24 ROIs and 
means were calculated. Average integrated densities of 
all animals per group were then compared between the 
groups.
Micro‑computed tomography
For micro-computed tomography (micro-CT), 20  ml 
Microfil Silicone Rubber (MV-122, Flow Tech, Carver, 
MA, USA) containing 5% of MV Curing Agent (Flow 
Tech) was applied instead of India ink in one animal 
(POD 15). A customized Micro-CT scanner (Y.Fox, 
Yxlon, Garbsen, Germany) with an open multifocus 
X-ray tube (10–160 kV; focal spot sizes 1–5 μm), a CNC 
manipulator, and a 14-bit direct amorphous silicon flat 
panel detector (Varian PaxScan 2520 D/CL; Varian, Palo 
Alto, CA, USA) was used. Data were analyzed with Osi-
rix v. 4.1.1 (Pixmeo, Geneva, Switzerland).
Bioinformatics analysis
Statistical analysis was performed using R (versions 
3.3.2/3.3.3; http://www.r-proje ct.org). Samples from 
sham-operated rats served as controls. Raw data gener-
ated by the Agilent Feature Extraction image analysis 
software was quantile normalized, and signal intensities 
of both miRNAs and mRNAs were  log2-transformed 
before further analysis. P-values were corrected for mul-
tiple testing using the Benjamini–Hochberg procedure. 
For RT-qPCR, the DataAssist™ Software v3.0 (Applied 
Biosystems) was used to calculate the fold-changes in 
miRNA and mRNA expression by the equation  2−ΔΔCT 
[26]. Correlation of miRNA and mRNA data was per-
formed with the Spearman correlation. Student’s T-test 
was used to compare mean Integrated Densities of 
immunohistochemical analysis.
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Results
MicroRNA microarray analysis
Microarray analysis of samples from AV shunts explanted 
on POD 5 revealed that 15 miRNAs were up-regulated 
and 19 miRNAs were down-regulated as compared 
to controls. On POD 10, 15 miRNAs were up-regu-
lated, whereas only miR-203a-3p was down-regulated. 
The strongest deregulation of miRNA expression was 
observed on POD 15 with 40 miRNAs being up-regulated 
and 16 miRNAs being down-regulated, respectively. A 
bimodal distribution of miRNA expression was observed 
across the different groups: Specific miRNAs were dereg-
ulated only in the early postoperative period (POD 5) 
with 9 miRNAs being up- and 14 miRNAs being down-
regulated. A different subset of miRNAs was deregulated 
in the late postoperative period, with 22 miRNAs being 
up-regulated and 16 miRNAs being down-regulated only 
on POD 15. Three miRNAs, namely miR-19b-3b, miR-
223-3p, and miR-340-5p, were up-regulated in all groups 
(fold change (FC) > 1.5, P < 0.05 for all comparisons) 
(Fig. 2a). A complete list of significantly deregulated miR-
NAs is shown in Additional file 1: Table S2.
mRNA microarray analysis
Microarray analysis of mRNA expression revealed the 
strongest deregulation on POD 5, with 6269 mRNAs 
Fig. 2 Deregulated microRNAs and messenger RNAs. Venn diagrams showing numbers of up‑ and down‑regulated microRNAs (miRNAs) (a), as well 
as of up‑ and down‑regulated messenger RNAs (mRNAs) (b) in the examined groups compared to controls. POD postoperative day
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being up-regulated and 5246 mRNAs being down-
regulated respectively. On POD 10, 1956 mRNAs were 
up-regulated and 1994 mRNAs were down-regulated. 
In contrast to miRNA expression, which exhibited a 
stronger deregulation on POD 15 compared to POD 
10, comparable amounts of deregulated mRNAs were 
observed on POD 15 with 1757 mRNAs being up-regu-
lated and 1861 mRNAs being down-regulated, respec-
tively. In all groups, 1016 mRNAs were up-regulated, 
whereas 1186 mRNAs were down-regulated (Fig.  2b). 
Among the deregulated mRNAs in samples from AV 
shunts, a marked over-expression of cytokines, espe-
cially chemokines, interleukins, and tumor necrosis fac-
tor (TNF) associated genes was observed. Moreover, a 
striking up-regulation of oxygenation-associated genes 
[HIF1A, heme oxygenase 1 (HMOX1)] as well as angio-
poetic growth factors [VEGFA, platelet derived growth 
factors (PDGF)] and their downstream signaling factors 
was observed across all groups. We observed a signifi-
cant down-regulation of antiangiogenic proteins in AV 
shunts: angiotensinogen (AGT) and angiotensinogen 
converting enzyme (ACE), as well as the thrombospon-
dins 3 and 4 (THBS3, THBS4) were continuously down-
regulated. Forkhead box C1 (FOXC1), synaptojanin-2 
binding protein (SYNJ2BP) and delta-like 1 (DLL1) 
were down-regulated in all groups as well. Endothelial 
nitric oxide synthase (NOS3, eNOS) was significantly 
downregulated on POD 15. On POD 5 and 10 negative 
fold-changes were observed for eNOS but statistical sig-
nificance was not met. For Kruppel-like factor 2 (KLF2), 
a significant downregulation was found on POD 5 (FC: 
− 2.25), whereas statistical significance was not met on 
POD 10 and 15, however fold-changes were also nega-
tive. Detailed FCs of selected mRNAs are shown in Addi-
tional file 1: Table S3 (P < 0.05 for all comparisons).
Correlation of miRNA and mRNA microarray data
In order to identify miRNA-regulated pathways of 
flow-stimulated angiogenesis, a correlation analysis of 
miRNA and mRNA expression data was performed. On 
POD 5, 7495 miRNA/mRNA pairs with a negative cor-
relation were found (P < 0.05; r ≤ − 0.5). On POD 10 and 
15, 969 respectively 2253 deregulated miRNA/mRNA 
pairs with negative correlations were evident (P < 0.05; 
r ≤ − 0.5). In the POD 5 group, 48 negatively correlat-
ing miRNA/mRNA pairs were identified, for which the 
respective mRNAs were up-regulated and associated 
with GO terms for positive regulation of angiogenic 
processes (i.e., up-regulated inducers of angiogenesis). 
In five of these inversely correlating miRNA/mRNA 
pairs, the mRNA was identified as a predicted target of 
the respective miRNA according to TargetScan: C–X–C 
chemokine receptor 2 (CXCR2) with let-7c-5p, let-7b-5p, 
miR-27b-3p, and miR10b-5p, respectively, as well as 
interleukin-1 alpha (IL1A) with miR-27b-3p. Nine nega-
tively correlating miRNA/mRNA pairs were found on 
POD 5, for which the respective mRNAs were down-
regulated and associated with GO terms for negative 
regulation of angiogenesis (i.e. down-regulated inhibi-
tors of angiogenesis). In four of these pairs, specific tar-
get interactions were present: SYNJ2BP and miR-223-3p, 
and miR-19b-3p as well as ephrin receptor 2 alpha 
(EPHA2) and miRNAs 130b-3p, and 223-3p respectively. 
On POD 10, six negatively correlating miRNA/mRNA 
pairs were found, for which mRNAs were down-regu-
lated and associated with GO terms for negative regula-
tion of angiogenesis. Predicted target interactions were 
present between SYNJ2BP and miR-223-3p as well as 
miR-19b-3p. In the POD 15 group, seven negatively cor-
relating miRNA/mRNA pairs were identified, for which 
the respective mRNAs were up-regulated and associ-
ated with GO terms for positive regulation of angiogen-
esis. However, none of these pairs were predicted targets 
according to TargetScan. We identified 14 negatively cor-
relating miRNA/mRNA pairs on POD 15, for which the 
respective mRNAs were down-regulated and associated 
with GO terms for negative regulation of angiogenesis. 
Among these pairs, the predicted target interactions of 
SYNJ2BP and miRNAs 223-3p and 19b-3p was also pre-
sent. Moreover, predicted interactions between SYNJ2BP 
and miR-449a-5p as well as between FOXC1 and miR-
511-3p were observed (r < − 0.5, P < 5 × 10−5 for all cor-
relations) (Table 1, Figs. 3, 4).
Validation of selected miRNAs and mRNAs by RT‑qPCR
In order to validate the microarray data by RT-qPCR we 
selected three miRNAs (miR-19b-3p, miR-340-5p, and 
miR-223-3p), that were significantly up-regulated in all 
examined groups (POD 5, 10, and 15) as well as miR-
31a-5p which was up-regulated on POD 10 and POD 15 
and miRNA miR-210-3p which was up-regulated only on 
POD 15. Moreover, we chose let-7c-5p, which was sig-
nificantly down-regulated only on POD 5, and let-7b-5p, 
which was down-regulated on POD 5 and 15. We selected 
two key regulators of angiogenesis, namely VEGFA and 
HIF1A [27], which were up-regulated on POD 5 and 10, 
as well as TLR6, which was up-regulated on POD 5 and 
15. Moreover, we selected NDRG2 and THBS3, which 
were down-regulated in all groups.
Aliquots from the same samples used for microarray 
analysis were used for RT-qPCR validation (POD 5: n = 3, 
POD 10: n = 6 and POD 15: n = 7; controls: n = 7). Due 
to the small size of the tissue specimens, four samples 
from the POD 5 group and one sample from the POD 10 
group yielded not enough RNA for RT-qPCR analysis. 
For each of the seven miRNAs, except for miR-210-3p 
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and miR-31a-5p in the POD 5 group, RT-qPCR analysis 
revealed concordant expression changes to the microar-
ray analysis in all groups, e.g. miR-223-3p, miR-19b-3p 
and miR-340-5p showed an increased expression in all 
groups (POD 5, 10, 15) compared to controls in both 
microarray and RT-qPCR analysis. Likewise, let-7b-5p 
and let-7c-5p showed a reduced expression across all 
groups (Table 2).
For mRNAs, RT-qPCR analysis uniformly revealed 
concordant expression changes to the microarray analysis 
across all examined groups. In accordance with microar-
ray data VEGFA, HIF1A and TLR6 were up-regulated, 
whereas NDRG2 and THBS3 were down-regulated in all 
groups.
The miRNA and mRNA expression changes in AV 
shunts compared to controls were concordant through-
out for all miRNAs and mRNAs, yet were partly below 
the significance threshold, apparently due to the reduced 
sample size in the RT-qPCR analysis, especially in the 
POD 5 group. Having encountered no contradictory 
results as to miRNA and mRNA expression changes, we 
did not opt to increase the sample size, i.e., the number 
of sacrificed rats, for RT-qPCR validation purposes alone, 
in accordance with the Animal Welfare Act. In summary, 
RT-qPCR analysis corroborated the results of the micro-
array analysis for both miRNAs and mRNAs in terms 
of concordant expression changes across all examined 
groups (Table 3).
Histologic analysis and micro‑CT
Histologic analysis of hematoxylin/eosin-stained cross-
sections of paraffin-embedded AV shunt constructs 
revealed early intramural vessel sprouting on POD 5 
(Fig.  5a). Neoangiogenesis within the acellular matrix 
surrounding both saphenous artery and vein was clearly 
visible on POD 10. An accumulation of erythrocytes 
around the areas of neoangiogenesis was visible on POD 
10, likely due to a high intraluminal pressure during ink 
perfusion of the AV shunts, causing cell leakage through 
the fragile vascular walls of the developing vascula-
ture (Fig. 5b). On POD 15, neoangiogenesis had further 
expanded and spanned an area equaling the diameter of 
the main vessels (Fig.  5c). Analysis of micro-CT images 
confirmed a dense microvascular sprouting from the AV 
shunt vessels on POD 15 (Fig. 1 c).
Table 1 Inverse correlations between micro-RNAs and up-regulated messenger RNAs (mRNA) which induce angiogenesis 
as well as down-regulated mRNAs which inhibit angiogenesis
Weighted context++ scores and percentiles were calculated with TargetScan (release 7.1)
GO gene ontology, POD postoperative day, CXCR2 C–X–C motive chemokine receptor 2, IL1A interleukin 1 alpha, SYNJ2BP synaptojanin-2 binding protein, EPHA2 
ephrin receptor 2 A, FOXC1 forkhead box C1
miRNA Gene symbol Mean fold‑
change 
miRNA
Mean fold‑
change 
mRNA
GO term Correlation P‑value Weighted 
context++ score
Weighted 
context++ score 
percentile
mRNAs inducing angiogenesis
 POD 5
  let‑7c‑5p CXCR2 − 4.30 10.92 0045766 − 0.66 3.31 × 10−6 − 0.193 79
  let‑7b‑5p CXCR2 − 3.23 10.92 0045766 − 0.64 3.47 × 10−6 − 0.157 74
  miR‑27b‑3p CXCR2 − 2.77 10.92 0045766 − 0.6 1.50 × 10−5 − 0.157 91
  miR‑10b‑5p CXCR2 − 3.76 10.92 0045766 − 0.57 3.58 × 10−5 − 0.414 98
  miR‑27b‑3p IL1A − 2.77 35.67 0045766 − 0.59 1.82 × 10−5 − 0.203 94
mRNAs inhibiting angiogenesis
 POD 5
  miR‑130b‑3p EPHA2 4.51 − 3.18 0016525 − 0.61 9.76 × 10−6 − 0.069 73
  miR‑223‑3p EPHA2 6.76 − 3.18 0016525 − 0.6 1.46 × 10−5 − 0.134 86
  miR‑223‑3p SYNJ2BP 6.76 − 2.74 1903671 − 0.73 1.85 × 10−7 − 0.013 37
  miR‑19b‑3p SYNJ2BP 3.63 − 2.74 0016525 − 0.58 2.96 × 10−5 − 0.052 52
 POD 10
  miR‑19b‑3p SYNJ2BP 2.06 − 2.19 0016525 − 0.58 2.96 × 10−5 − 0.052 52
  miR‑223‑3p SYNJ2BP 3.95 − 2.19 0016525 − 0.73 1.85 × 10−7 − 0.086 77
 POD 15
  miR‑511‑3p FOXC1 6.52 − 6.39 0016525 − 0.56 4.33 × 10−5 − 0.038 62
  miR‑223‑3p SYNJ2BP 5.12 − 1.99 0016525 − 0.73 1.85 × 10−7 − 0.086 77
  miR‑449a‑5p SYNJ2BP 1.75 − 1.99 0016525 − 0.64 5.74 × 10−7 − 0.143 74
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Immunohistochemistry
Based on the results of the microarray analysis showing a 
strong overexpression of the cytokines CXCL2 and IL1A 
at the mRNA level, we selected these two genes for fur-
ther validation at the protein level. Immunohistochemi-
cal analysis of IL1A and CXCL2 expression in AV shunt 
and control vein cross sections showed a significant 
increase in CXCL2 and IL1A expression in the endothe-
lial cells of AV shunts on POD 5, 10 and 15 compared to 
control veins. Comparison between AV shunt subgroups 
revealed a significant increase in expression for both pro-
teins at POD 15 compared to POD 5 and 10 respectively. 
Expression of CXCL2 at POD 10 had decreased signifi-
cantly compared to POD 5, whereas no significant dif-
ferences between POD 5 and 10 were evident for IL1A 
(Table 4, Fig. 6).
Discussion
Angiogenesis occurs either as a physiological response 
of the organism to locally challenged blood supply after 
either acute (trauma, embolism) or chronic (atheroscle-
rosis) damage, or as a pathological process triggered by 
proangiogenic factors secreted from tumor cells [28]. 
Due to the limited recovery time granted by malnour-
ished tissue, neoangiogenesis must be a rapid yet well-
orchestrated process of three-dimensional proliferation 
and differentiation of ECs and VSMCs interacting with 
the surrounding tissue in need of supply. Mechanical 
stimuli indicating critical dysfunction of existing vessels 
are transferred via mechanosensory proteins and sign-
aling cascades into expression of proangiogenic factors 
[29]. Studies on cell cultures have also identified com-
plex networks of miRNAs governing rapid changes of 
Fig. 3 a Inverse correlations of microRNAs and messenger RNAs with relevance to angiogenesis. Deregulated microRNAs (miRNAs) and messenger 
RNAs (mRNAs) with significant inverse correlations as well as association with angiogenesis‑related gene ontology (GO) terms and predicted 
target interactions according to TargetScan. Green background: up‑regulated mRNAs. Red background: down‑regulated mRNAs. Connections 
between miRNAs and mRNAs represent significant inverse correlations (r < − 0.5, P < 5 × 10−5). b Schematic workflow of the study for identification 
of miRNA‑regulated pathways in flow‑stimulated angiogenesis. Spearman correlation plots show significant inverse correlations between the 
expression levels of synaptojanin‑2 binding protein (SYNJ2BP) and miR‑449‑5p (c) as well as miR 223‑3p (d), ephrin receptor kinase 2 (EPHA2) and 
miR‑223‑3p (e), forkhead box C1 (FOXC1) and miR‑511‑3p (f), interleukin‑1 alpha (IL1A) and miR‑27b‑3p (g), as well as C–X–C chemokine receptor 2 
and let‑7b‑5p (h)
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gene activities during this process [10]. In  vitro studies, 
even if three-dimensional cell culturing techniques are 
employed [30] are unable to represent the molecular pic-
ture of neoangiogenesis in its full complexity, as they can 
neither properly simulate the continuously changing fluid 
mechanics nor the multitude of interacting cell types 
within an emerging vascular network. This is why we pre-
sent, to the best of our knowledge, the first in vivo study 
investigating the response of biochemical pathways to 
elevated vascular shear stress and their interaction with 
miRNAs over several phases of neoangiogenesis.
Our data show strong and significant changes in 
miRNA and gene expression profiles over time within the 
vascular wall of AV shunts compared to sham-operated 
veins. Since the only difference between treatment and 
control groups in our experiment was the presence of an 
elevated blood flow in the treatment group, the observed 
differences in miRNA expression are likely evoked by 
elevated vascular shear stress within AV shunts. Notably, 
changes in miRNA and gene expression patterns precede 
the sprouting of new blood vessels from AV shunts, since 
significant deregulations of miRNA as well as mRNA 
expression arise already on POD 5, when functional 
microvasculature is not yet present around the main ves-
sels. This finding demonstrates that alterations in molec-
ular signaling in response to elevated blood flow occur 
rapidly and are already detectable when the physical 
outgrowth of blood vessels is still limited to intramural 
sprouting of new blood vessels within the vascular wall of 
the main vessels (Fig. 5a).
Cytokines
Cytokines, among them chemokines, interleukins, and 
the TNF family, play a well-established role in the early 
induction of angiogenesis through up-regulation of 
growth factors like VEGFA [31]. C–X–C and C–C motif 
chemokines showed a strong mRNA overexpression in 
AV shunts. CXCL2, 3, and 11, as well as CCL6 and 9 were 
significantly upregulated on POD 5 compared to con-
trols. We confirmed CXCL2 overexpression in ECs of AV 
shunts on the protein level on POD 5, 10 and 15 com-
pared to control veins by immunohistochemical staining. 
CXCL2 was upregulated on the mRNA level in all AV 
shunt groups, however, statistical significance was missed 
Fig. 4 Differential expression of microRNAs and messenger RNAs with relevance to angiogenesis. Mean expression levels ± 1 SEM (a) and mean 
fold‑changes (b) compared to controls (CO) for microRNAs (miRNAs) with significant inverse correlations and target interactions with messenger 
RNAs (mRNAs) (c, d) in the analyzed groups. Mean expression levels for miRNAs are shown log10‑transformed for illustrative purposes
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on POD 10 (FC: 11, adjusted P: 0.25) and POD 15 (FC: 
13, adjusted P: 0.13) which may be related to the rela-
tively low sample size. In wound healing, CXCL2 is up-
regulated 3  days after skin incision and is also involved 
in bronchial angiogenesis [32, 33]. Studies on peripheral 
blood cells and murine skin grafts subjected to extracor-
poreal shock wave treatment demonstrated a relationship 
between neoangiogenesis and a mechanically induced 
cytokine up-regulation [34, 35]. Our in vivo data indicate 
that elevated vascular shear stress leads to a strong up-
regulation of chemokines as well as their receptors within 
the vascular wall, which seem to determinants of flow-
stimulated angiogenesis.
Among the down-regulated miRNAs on POD 5, let-
7b-5p, let-7c-5p, miR-27b-3p, and miR-10b-5p exhib-
ited inverse correlations with C–X–C motif chemokine 
receptor 2 (CXCR2), which we found to be 11-fold 
up-regulated and a predicted target of these miRNAs. 
CXCR2 plays a pivotal role in angiogenesis by mediating 
recruitment of endothelial progenitor cells via its ligands 
CXCL1 and CXCL2 and acts as a receptor to several 
CXCL-chemokines, among them CXCL2 and CXCL3 
[36], sharing its expression profile over time with them 
in our study. Moreover, CXCR2 stimulates cell migration 
via adaptor protein 2 (AP2) [37], which we found to be 
up-regulated on POD 5 and 10.
Our data indicate that elevated shear stress in AV 
shunts is associated with a down-regulation of let-7b-5p, 
let-7c-5p, miR-27b-3p, and miR-10b-5p, which likely 
leads to a disinhibition of CXCR2 in the early postop-
erative period, being an important determinant of flow-
induced angiogenesis in  vivo. Other chemokines, like 
CCL3, CCL12, and CCL20 as well as CXCR4 and CCR5 
were steadily overexpressed until POD 15, apparently 
acting as “intermediate-” and “late-phase” cytokines. Two 
chemokines, CXCL14 and CXCL21, were down-regu-
lated most prominently in the intermediate and late post-
operative periods. Both chemokines are potent inhibitors 
of angiogenesis in various types of cancers [38, 39]. In 
accordance with these studies, our data indicate that a 
down-regulation of these chemokines in AV shunts con-
tributes to neoangiogenesis.
Interleukins were the second strongly over-expressed 
group of cytokines in our model, with IL1A and 
Table 2 Quantitative real-time polymerase chain reaction (qPCR) and miRNA microarray analysis for selected miRNAs
POD postoperative day
miRNA qPCR miRNA microarray
Fold change P‑value Regulation Fold change P‑value Regulation
POD 5
 miR‑19b‑3p 1.40 0.2180 Up 3.63 0.0243 Up
 miR‑210‑3p − 1.3 0.2350 Down 3.90 0.1504 Up
 miR‑223‑3p 2.78 0.2260 Up 6.75 6.67 × 10−6 Up
 miR‑31a‑5p − 1.08 0.8740 Down 3.37 0.4048 Up
 miR‑340‑5p 1.61 0.2760 Up 3.32 0.0087 Up
 let‑7b‑5p − 2.04 0.2200 Down − 3.23 0.0144 Down
 let‑7c‑5p − 7.14 0.0040 Down − 4.30 0.0130 Down
POD 10
 miR‑19b‑3p 1.84 0.0600 Up 2.06 0.0364 Up
 miR‑210‑3p 1.75 0.0110 Up 5.24 0.1289 Up
 miR‑223‑3p 3.25 0.0630 Up 3.95 0.0266 Up
 miR‑31a‑5p 6.87 0.0030 Up 18.49 0.0097 Up
 miR‑340‑5p 3.23 0.0490 Up 2.82 0.0193 Up
 let‑7b‑5p − 2.22 0.0080 Down − 2.07 0.1736 Down
 let‑7c‑5p − 2.38 0.0110 Down − 2.24 0.1611 Down
POD 15
 miR‑19b‑3p 2.36 0.1390 Up 1.90 0.0464 Up
 miR‑210‑3p 1.97 0.0050 Up 5.85 0.0450 Up
 miR‑223‑3p 3.17 0.0050 Up 5.12 0.0236 Up
 miR‑31a‑5p 9.74 0.0080 Up 22.08 0.0046 Up
 miR‑340‑5p 3.80 0.0570 Up 3.74 0.0089 Up
 let‑7b‑5p − 1.75 0.0420 Down − 2.39 0.0458 Down
 let‑7c‑5p − 1.75 0.0540 Down − 2.10 0.1069 Down
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interleukin-1 beta (IL1B) showing a significant upregu-
lation on POD 5. IL1A is known to promote angiogen-
esis by inducing inflammatory cell VEGF synthesis and 
secretion [40]. The expression of miR-27b-3p, which was 
twofold down-regulated on POD 5, negatively correlated 
with IL1A expression. A predicted target interaction was 
revealed for this miRNA/mRNA pair, indicating that up-
regulation of IL1A in AV shunts is likely due to reduced 
post-transcriptional silencing by miR-27b-3p. IL1A over-
expression in ECs of AV shunts was confirmed by immu-
nohistochemical staining at the protein level for all AV 
shunt groups, whereas mRNA overexpression missed sta-
tistical significance on POD 10 (FC: 11, adjusted P: 0.12) 
and POD15 (FC: 7, adjusted P: 0.06) which is likely influ-
enced by sample size.
IL-33, however, was down-regulated in all groups 
which is in accordance with the literature describing it as 
a marker for endothelial quiescence [41].
Another entity of proangiogenic cytokines over-
expressed in AV shunts are members of the tumor 
necrosis factor (TNF) family, among these TNF alpha 
and its receptor (TNFR2) which were up-regulated in 
the early postoperative period. In cell cultures it has 
been shown that TNF is up-regulated in response to 
mechanical strain [42]. In accordance with our obser-
vation, Sainson et  al. reported that a 2–3  day TNF 
pulse on endothelial cells stimulates angiogenesis by 
inducing platelet derived growth factor B (PDGFB) 
and vascular endothelial growth factor receptor 2 
(VEGFR2) [43]. Lipopolysaccharide induced TNF fac-
tor (LITAF), a transcription factor which was con-
tinuously overexpressed in samples from AV shunts, 
upregulates TNF alpha as well as VEGF [44, 45]. Our 
data demonstrate that members of the TNF family are 
up-regulated in response to elevated vascular shear 
stress under in  vivo conditions and are likely impor-
tant determinants of flow-stimulated angiogenesis.
The sudden exposure of ECs to an arterial environ-
ment with elevated vascular shear stress leads to a state 
of EC activation, characterized by an upregulation of 
inflammatory factors such as chemokines and other 
cytokines, growth factors, as well as a downregulation 
of protective factors such as KLF2 [46]. As the pro-
cess of angiogenesis is closely related to inflammation, 
with many pro-inflammatory factors such as several 
chemokines also acting pro-angiogenic, the miRNA-
mRNA interactions we present constitute intriguing 
therapeutic targets for investigation in future studies 
pursuing treatment strategies for systemic inflamma-
tory disorder such as rheumatoid arthritis.
Table 3 Quantitative real-time polymerase chain reaction (qPCR) and mRNA microarray analysis for selected mRNAs
POD postoperative day, HIF1A hypoxia-inducible factor-1 A, TLR 6 toll-like receptor 6, VEGFA vascular endothelial growth factor-A, THBS3 thrombospondin 3, NDRG2 
NMYC downstream-regulated gene 2, POD postoperative day
mRNA qPCR miRNA microarray
Fold change P‑value Regulation Fold change P‑value Regulation
POD 5
 HIF1A 2.18 0.214 Up 1.97 0.0003 Up
 TLR6 4.00 0.071 Up 4.11 0.0003 Up
 VEGFA 3.45 0.22 Up 4.41 0.0007 Up
 THBS3 − 14.29 0.001 Down − 8.78 5.33 × 10−6 Down
 NDRG2 − 33.33 0.002 Down − 21.00 0.0005 Down
POD 10
 HIF1A 1.69 0.049 Up 1.59 0.0380 Up
 TLR6 2.72 0.061 Up 2.22 0.1089 Up
 VEGFA 3.46 0.015 Up 3.12 0.0379 Up
 THBS3 − 7.14 0.001 Down − 1.36 0.0050 Down
 NDRG2 − 7.69 0.003 Down − 10.91 0.0157 Down
POD 15
 HIF1A 1.19 0.288 Up 1.38 0.3585 Up
 TLR6 2.22 0.003 Up 2.46 0.0106 Up
 VEGFA 2.32 0.066 Up 2.71 0.1847 Up
 THBS3 − 11.11 0.001 Down − 1.57 0.0008 Down
 NDRG2 − 11.11 0.003 Down − 8.48 0.0002 Down
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Oxygenation‑associated genes
Our analysis revealed heme oxygenase-1 (HMOX1) to 
be among the most strongly up-regulated genes, with a 
peak expression on POD 5 (24-fold) and over tenfold up-
regulation in AV shunts compared to controls through-
out. HIF1A was significantly up-regulated on POD 5 and 
10, however to a lesser extent compared to HMOX1. 
The oxygenation status of tissue is a major determinant 
of angiogenesis, and hypoxia is looked upon as the com-
mon denominator for angiogenesis and inflammation 
[47]. Oxygenation-sensitive proteins, namely HIF1A 
and HMOX1, respond to insufficient oxygen supply by 
inducing angiogenic growth factors of the VEGF/PDGF 
group and their receptors in strong synergy with inflam-
matory cytokines [48, 49]. HIF1A is known to be a key 
transcriptional activator of angiogenesis, transferring 
hypoxic stress into angiogenic stimuli through up-reg-
ulation of growth factors and induction of macrophage-
mediated inflammation [27]. Bhang et  al. demonstrated 
that combined HIF1A/HMOX1 gene therapy in mice 
is more efficient in inducing angiogenesis than either 
single-gene therapy [50]. In a mouse model of vascu-
lar injury, Kang et  al. showed that HMOX1 is released 
from endothelial cells in response to vascular shear stress 
[51]. Therefore, our data indicate that HMOX1 likely 
represents an autonomous agent in flow-stimulated 
Fig. 5 Histologic analysis of arteriovenous shunts. Histologic analysis of hematoxylin/eosin stained cross sections of explanted vascular constructs 
on postoperative day (POD) 5 (a, b), 10 (b, c), and 15 (d, e) show ink‑perfused vessel lumina of both saphenous artery (*) and vein (#). Early 
intramural vessel sprouting was detected within the wall of the saphenous artery (*) on POD 5 (b, black arrow). Neoangiogenesis within the 
acellular dermal matrix (ADS) surrounding the saphenous vein (#) was clearly visible on POD 10 (blue arrowheads, d). Neoangiogenesis had strongly 
expanded and surrounded both artery (*) and vein (#) on POD 15 (e, f, blue arrowheads). An accumulation of erythrocytes (E) around the main 
vessels was seen on POD 10 (c and d)
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angiogenesis not requiring activation through cytokines. 
A strong down-regulation of NDRG2 was present in all 
groups of AV shunts. The N-myc oncogene (MYCN) was 
overexpressed on POD 5 and has been shown to repress 
NDRG2 [52]. Transfection of breast carcinoma cells with 
NDRG2 decreases the expression and proangiogenic 
activity of HIF1A and VEGF [53]. Hence, it is likely that 
the down-regulation of NDRG2 in AV shunts supports 
the proangiogenic effects of hypoxia-related genes.
S100A8 and S100A9, which code for calcium-bind-
ing proteins forming a heterodimer, calprotectin [54], 
showed a strong over-expression in AV shunts on POD 
5. They were shown to promote endothelial tube forma-
tion in HUVEC cultures [55]. Ahn et  al. demonstrated 
that transcriptional activation of HIF1A promotes 
angiogenesis through VEGF and S100A8 [56], illustrat-
ing the cooperative action of hypoxia-associated fac-
tors, S100A proteins, and VEGF. The main calprotectin 
receptor is toll-like receptor 4 (TLR4), which we found 
overexpressed on POD 5 and 15 as well [57], along 
with the proangiogenic toll-like receptor 6 (TLR6) [58]. 
We therefore assume that shear stress-induced HIF1A 
Table 4 Immunohistochemical analysis of  C–X–C chemokine ligand 2 (CXCL2) and  interleukin-1 alpha (IL1A) protein 
expression in AV shunt and control vein (Co) cross sections
POD postoperative day, SEM standard error of the mean
Group Mean integrated density, µm2 × pixel 
(SEM)
Endothelium
P (vs. Co)
CXCL2
P (vs. POD 5)
CXCL2
P (vs. POD 10)
CXCL2
P (vs. POD 15)
CXCL2
CXCL2 IL1A IL1A IL1A IL1A IL1A
Co 5173 (351) 2987 (331) 0.0005 10−5 9 × 10−15
0.02 0.003 6 × 10−6
POD 5 7838 (559) 5186 (501) 0.0005 0.01 0.03
0.02 0.21 0.0003
POD 10 6473 (265) 4590 (207) 10−5 0.01 7 × 10−10
0.003 0.21 10−10
POD 15 9251 (345) 7606 (400) 9 × 10−15 0.03 7 × 10−10
6 × 10−6 0.0003 10−10
Fig. 6 Immunohistochemical staining for CXCL2 and IL1A. Immunohistochemical analysis of C–X–C chemokine ligand 2 (CXCL2) (a–c) and 
interleukin‑1 alpha (IL1A) protein expression (d–f) in AV shunt and control vein (Co) cross sections show a significant increase in the expression of 
both proteins in the endothelial cells of AV shunts on postoperative day (POD) 5 (a, d) and an even stronger expression on POD 15 (c, f) compared 
to control veins (a, d). The black Indian ink filling the vessel lumen (*) appears detached from the endothelium in some sections due to cutting 
artifacts
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up-regulation in AV shunts, which is fostered by NDRG2 
down-regulation, leads to concurrent over-expres-
sion of S100A8 and VEGF, promoting endothelial tube 
formation.
Forkhead box C1
The transcription factor forkhead box C1 (FOXC1) was 
steadily down-regulated in AV shunts, most promi-
nently on POD 15. We noted the expression level of miR-
511-3p, which was strongly up-regulated on POD 15, to 
negatively correlate with FOXC1 expression. FOXC1 was 
found to be a predicted target of miR511-3p. FOXC1 is 
a key regulator of early angiogenesis, and determines 
endothelial cell fate and gene expression at early stages 
[59]. One of its physiological functions is the limitation 
of angiogenesis in the cornea, as demonstrated in FOXC1 
knockout mice [59]. Conversely, conditional deletion of 
FOXC1 from VSMCs causes endothelial cell hyperplasia 
[60]. It has been demonstrated that FOXC1 deficiency 
leads to an up-regulation of matrix metalloproteinases 
(MMPs), including MMP9 [59, 61], which was also up-
regulated on POD 5 in our study. MMP9 has the ability to 
cleave VEGF from the ECM, thereby increasing its con-
centration and facilitating angiogenesis [62]. Data from 
our study indicate that an up-regulation of miR511-3p, 
purportedly due to elevated shear stress in the AV shunts, 
leads to a down-regulation of FOXC1 which contributes 
to angiogenesis in rat AV shunts.
Angiotensin and thrombospondins
We found both angiotensinogen (AGT) and angiotensin-
converting enzyme (ACE) to be down-regulated in all 
groups, which is in accordance with the anti-angiogenic 
function of angiotensin and its cleaved derivatives [63]. 
The down-regulation of the angiotensin pathway may be 
driven by cytokines, as administration of TNF-alpha and 
IL-1 beta to EC cell cultures downregulates ACE [64]. 
Thrombospondins (THBS) are a group of ECM proteins 
associated with an anti-angiogenic function, in particular 
THBS1 and THBS2 [65], whereas THBS3 and THBS4 are 
poorly characterized so far [66]. We found both THBS3 
and THBS4 to be strongly down-regulated in all groups, 
unlike THBS1 and THBS2. We ascertained this find-
ing of the microarray analysis by RT-qPCR validation of 
THBS3. Thus, THBS3 and THBS4 may have as yet unde-
scribed anti-angiogenic functions.
Synaptojanin‑2 binding protein/delta‑like 1/apelin
In all AV shunt groups, a steady down-regulation of 
SYNJ2B was evident. SYNJ2BP expression correlated 
negatively with miR-223-3p—one of the most overex-
pressed miRNAs in AV shunts—for which predicted tar-
get interactions are present. Negative correlations were 
also present between SYNJ2BP and miR-19b-3p (POD 5 
and 10) as well as miR-449a-5p (POD 15) which also have 
predicted binding sites on the SYNJ2BP-mRNA. To date, 
regulation of SYNJ2B expression by miRNAs has not yet 
been reported. SYN2JBP has only recently been recog-
nized to be a regulator of angiogenesis. Adam et al. found 
that SYNJ2BP inhibits sprouting angiogenesis through 
enhancing the stability of the Notch ligands Delta-like 
1 and 4 (DLL1, DLL4) and decreasing the expression of 
VEGF receptors [67]. Moreover, they demonstrated that 
SYNJ2BP-silenced human endothelial cells form a vascu-
lar network with increased vascular density in immuno-
compromised mice. Along with SYNJ2BP, we found DLL1 
to be steadily down-regulated as well, while DLL4 expres-
sion was not significantly altered. DLL1 over-expression 
has been shown to attenuate tumor vascularization [68]. 
A crucial function of SYNJ2BP is the inhibition of apelin 
(APLN), a gene required for tip cell formation in sprout-
ing blood vessels [67, 69]. Apelin was strongly overex-
pressed in all AV shunt groups, indicating its importance 
for endothelial tip formation in the developing vascula-
ture of AV shunts. We assume that down-regulation of 
SYNJ2BP is mediated by post-transcriptional silencing 
through miR-223-3p and miR-19b-3p. Since a strong 
up-regulation of these two miRNAs was observed in all 
AV shunt groups, this phenomenon is likely triggered 
by hemodynamic forces due to elevated blood flow in 
the AV shunt. Disinhibition of apelin caused by SYNJBP 
down-regulation likely constitutes a previously unde-
scribed early factor in flow-stimulated angiogenesis.
Ephrin receptor kinases
The ephrin receptor kinases 3 and 4 (EPHA3, EPHA4) 
were significantly down-regulated in all AV shunt 
groups. EPHA2 was down-regulated only on POD 5 
and showed a significant negative correlation with miR-
130b-3p and miR-223-3p, for which predicted target 
interactions are present. The role of EPHA kinases in 
the formation and function of blood vessels is complex 
and only partially understood. It ranges from regulation 
of vascular permeability [70] to induction of angiogen-
esis [71]. Reports on the effects of EPHA2 inactiva-
tion are contradictory: Dobrzanski et al. described that 
interfering with EPHA2 signaling inhibits angiogen-
esis [72], whereas Okazaki et  al. observed abundant 
endothelial sprouts and thick capillary diameters in 
EPHA2-deficient mice [73]. Our data support the 
notion that flow-induced upregulation of miR-130b-3p 
and miR-223-3p lead to post-transcriptional silencing 
of EPHA2. The exact role of EPHA2 in flow-stimulated 
angiogenesis, however, remains to be determined and 
warrants future studies.
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KLF2 and eNOS
With regard to the expression of KLF2 and eNOS in our 
model, our data confirm previous microarray analyses 
in carotid artery ligation models showing a downregula-
tion of both genes due to a disturbed blood flow [74, 75]. 
The expression of both KLF2 and eNOS have been well 
characterized in response to various hemodynamic pat-
terns of blood flow and existing data have shown that 
laminar flow patterns lead to an activation of both genes 
[76], whereas a disturbed blood flow leads to a downreg-
ulation of eNOS and KLF2 as has been demonstrated in 
carotid artery ligation models [74, 75]. To date, system-
atic investigations of blood flow in the AV shunt model 
are limited to assessment of absolute levels of blood flow 
and shear stress over time, which have been performed 
by our group and others [21, 77] but the exact flow pat-
tern have not yet been investigated. Our data on KLF2 
and eNOS expression fit with a pattern of disturbed flow, 
however, systematic analysis of flow patterns are needed 
to better define their impact on gene expression in this 
model. Since it is well known that eNOS mediates pro-
angiogenic effects, our results indicate that the eNOS 
pathway is not a main determinant of neoangiogenesis in 
the AV shunt model.
Vascular growth factors
Growth factors of the VEGF and PDGF families and their 
receptors are core inducers of angiogenesis [78, 79]. In 
our study VEGFA and PDGFA were overexpressed on 
POD 5 and 10, and PDGFB was overexpressed on POD 
15. Moreover, the downstream effector of VEGF signal-
ing, phospholipase C gamma 2 (PLCG2) is up-regulated 
on POD 5, fitting with its role as an early determinant 
of sheer stress-induced signaling, as determined by 
Bazmara et  al. through in silico analysis [80]. All afore-
mentioned pathways, up-regulation of cytokines, oxygen-
ation-associated genes, as well as down-regulation of the 
FOXC1 and SYNJ2BP, culminate in an overexpression of 
vascular growth factors. The CXCL2/CXCR2 pathway, 
which we found strongly up-regulated in AV shunts, acti-
vates PLC beta 2 and PLCG2 as well as phosphoinositide-
3-kinase (PI3K) and its downstream gene HIF1A, all of 
which act as VEGF effectors [31].
We demonstrate a specific profile of deregulated miR-
NAs in vascular tissue from a rat model of elevated vas-
cular shear stress and indicate significant correlations 
and predicted interactions of these miRNAs with genes 
that regulate angiogenesis. Our study extends the current 
understanding of miRNA-regulated pathways in flow-
stimulated angiogenesis and identifies several promis-
ing targets for future studies on RNA-based therapeutic 
interventions [81]. Future translational research in this 
field may deliver new therapeutic approaches for miRNA-
driven enhancement of local angiogenesis, aimed at 
either rescuing critically ischemic tissue e.g. in patients 
with diabetic angiopathy or myocardial ischemia, or at 
fostering the engraftment of tissue transplants. The data 
presented here may also be applicable in future transla-
tional studies in the field of tissue engineering. The AV 
loop model is a reliable tissue engineering technique for 
creation of vascularized and transplantable soft tissue 
units and has a great potential for successful transla-
tion from animal models into clinical trials in the future 
[82]. The miRNA profile and specific candidate genes we 
report, can serve as targets for selective enhancement 
of neovascularization using synthetic miRNA-mimics 
or antagomirs. Conversely, the same understanding may 
provide new clues for the suppression of angiogenesis in 
cancer.
Conclusions
Our in  vivo data provide evidence that flow-stimulated 
angiogenesis resulting from elevated vascular shear stress 
is driven by an up-regulation of cytokines (e.g. CXCL2, 
IL1A) as well as oxygenation-associated genes (HIF1A, 
HMOX1), and by a down-regulation of the embryonic 
transcription factor FOXC1 as well as the mitochon-
drial membrane protein SYNJ2BP. Significant inverse 
correlations of the expression levels of these genes with 
their interacting miRNAs, namely the up-regulated miR-
223-3p, miR-130b-3p, miR-19b-3p, miR-449a-5p, and 
miR-511-3p as well as the down-regulated miR-27b-3p, 
miR-10b-5p, let-7b-5p, and let-7c-5p, illustrate that a 
deregulation of miRNA expression is likely responsible 
for the observed gene and protein expression changes. 
Thus, the timeline of events in flow-stimulated angio-
genesis in  vivo appears to start with elevated vascular 
shear stress leading to a deregulation of specific miR-
NAs, which affect the expression of CXCR2, IL1A, 
FOXC1, SYNJ2BP, and EPHA2. Elevated expression 
of chemokines, interleukins, as well as of HIF1A and 
HMOX1 along with a down-regulation of SYNJ2BP and 
FOXC1 promotes VEGF expression and neoangiogenesis.
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